General Retroviral Vector Questions

1. Is there information on the number of independent integration events in the transduced cell population?

2. Is there information, from either *in vitro* or *in vivo* studies, on the potential growth advantage of transduced T cells and for their potential *in vivo* selection? Do they show any proliferative advantage *in vitro* or in animal reconstruction studies?

General Retroviral Vector Questions

3. Is there any plan to use vectors that express the transgene conditionally? Are there any plans to use SIN retroviral constructs, to incorporate silencer elements or to include suicide elements into the vectors?

4. Do the investigators plan to carry out any large animal studies to test long-term effects and potential tumorigenicity?

General Retroviral Vector Questions

5. Is there evidence for the potential transforming and oncogenic properties of the transgene? How do cells behave *in vitro* and *in vivo* when they express this transgene? Are there any clues on this point from transgenic mice over-expressing the transgene?

6. How do the investigators propose to monitor the subjects and detect clonally expanding cells?

General Retroviral Vector Questions

7. Will the consent process include discussion of the appearance of T cell leukemia in Dr. Fischer's study of X-SCID?

8. How are the investigators monitoring subjects in similar ongoing trials, if any? Have they up-dated the informed consent process to reflect new knowledge of the emergence of leukemia in the Paris study?

General Retroviral Vector Questions

9. Is there information on the existence of transduced cells in the circulation of subjects in any of these ongoing trials? Any information on how many transduced cell clones exist in those subjects and how many integration sites?